Stribild(cobicistat)
Evotaz, Genvoya, Prezcobix, Rezolsta, Stribild, Symtuza, Tybost (cobicistat) is a small molecule pharmaceutical. Cobicistat was first approved as Stribild on 2012-08-27. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
BMS
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Tybost
CombinationsEvotaz, Genvoya, Prezcobix, Stribild, Symtuza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Atazanavir sulfate
+
Cobicistat
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EVOTAZ | Bristol Myers Squibb | N-206353 RX | 2015-01-29 | 1 products, RLD, RS |
Cobicistat
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TYBOST | Gilead Sciences | N-203094 RX | 2014-09-24 | 1 products, RLD, RS |
Cobicistat
+
Darunavir
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PREZCOBIX | Johnson & Johnson | N-205395 RX | 2015-01-29 | 1 products, RLD, RS |
Cobicistat
+
Darunavir
+
Emtricitabine
+
Tenofovir alafenamide fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SYMTUZA | Johnson & Johnson | N-210455 RX | 2018-07-17 | 1 products, RLD, RS |
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir alafenamide fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GENVOYA | Gilead Sciences | N-207561 RX | 2015-11-05 | 1 products, RLD, RS |
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| STRIBILD | Gilead Sciences | N-203100 RX | 2012-08-27 | 1 products, RLD, RS |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hiv infections | EFO_0000764 | D015658 | B20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
COBICISTAT, TYBOST, GILEAD SCIENCES INC | |||
| 2026-08-22 | ODE-260 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Cobicistat / Darunavir / Emtricitabine / Tenofovir Alafenamide Fumarate, Symtuza, Janssen Prods | |||
| 10786518 | 2038-07-19 | U-2978 | |
| 8754065 | 2032-08-15 | DS, DP | U-257, U-2352, U-2765 |
| 9296769 | 2032-08-15 | DS, DP | U-257, U-2352, U-2765 |
| 7390791 | 2025-04-17 | DS, DP | |
| Atazanavir Sulfate / Cobicistat, Evotaz, Bristol | |||
| 10039718 | 2032-10-06 | DP | |
| 8148374 | 2029-09-03 | DS, DP | U-1279, U-2353, U-2364, U-2365, U-2766, U-2767, U-2768, U-2939 |
| Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Alafenamide Fumarate, Genvoya, Gilead Sciences Inc | |||
| 8633219 | 2030-04-30 | DP | U-257 |
| 9891239 | 2029-09-03 | DP | U-257 |
| 7635704 | 2026-10-26 | DS, DP | U-257 |
| 8981103 | 2026-10-26 | DS, DP | |
| 7176220 | 2026-08-27 | DS, DP | U-257 |
| Cobicistat / Darunavir, Prezcobix, Janssen Prods | |||
| 7700645 | 2026-12-26 | DS, DP | |
| 8518987 | 2024-02-16 | DS, DP | |
| Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Disoproxil Fumarate, Stribild, Gilead Sciences Inc | |||
| 8592397 | 2024-01-13 | DP | U-257 |
| 8716264 | 2024-01-13 | DP | U-257 |
| 9457036 | 2024-01-13 | DP | U-257 |
| 9744181 | 2024-01-13 | DP | U-257 |
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR09: Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
— J05AR14: Darunavir and cobicistat
— J05AR15: Atazanavir and cobicistat
— J05AR18: Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
— J05AR22: Emtricitabine, tenofovir alafenamide, darunavir and cobicistat
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AX: Other therapeutic products in atc
— V03AX03: Cobicistat
HCPCS
No data
Clinical
Clinical Trials
94 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 4 | 10 | 11 | 4 | 31 |
| Hiv | D006678 | O98.7 | 8 | 1 | 4 | 7 | 3 | 23 | |
| Healthy volunteers/patients | — | 11 | — | — | 2 | — | 13 | ||
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | 4 | 1 | 1 | 6 |
| Neoplasms | D009369 | C80 | — | 1 | — | 1 | — | 2 | |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | 1 | — | 1 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | — | 1 | — | 1 |
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | 1 | — | 1 | |
| Coinfection | D060085 | — | — | — | 1 | — | 1 | ||
| Sleep wake disorders | D012893 | G47 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv-1 | D015497 | 1 | — | 1 | — | — | 2 | ||
| Coronavirus | D017934 | — | — | 1 | — | 1 | 2 | ||
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | — | 1 |
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | — | — | 1 | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 2 | — | — | — | — | 2 |
| Hepatitis c | D006526 | B19.2 | 1 | — | — | — | — | 1 | |
| Insulin resistance | D007333 | EFO_0002614 | 1 | — | — | — | — | 1 | |
| Non-small-cell lung carcinoma | D002289 | 1 | — | — | — | — | 1 | ||
| Latent tuberculosis | D055985 | Z22.7 | 1 | — | — | — | — | 1 | |
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 | ||
| Drug interactions | D004347 | 1 | — | — | — | — | 1 | ||
| Pancreatic ductal carcinoma | D021441 | 1 | — | — | — | — | 1 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | — | — | 1 | 1 |
| Job syndrome | D007589 | EFO_0003775 | D82.4 | — | — | — | — | 1 | 1 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 1 | 1 |
| Chronic hepatitis b | D019694 | EFO_0004197 | B18.1 | — | — | — | — | 1 | 1 |
| Bone diseases | D001847 | M89.9 | — | — | — | — | 1 | 1 | |
| Sexually transmitted diseases | D012749 | A50-A64 | — | — | — | — | 1 | 1 | |
| Covid-19 | D000086382 | U07.1 | — | — | — | — | 1 | 1 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | COBICISTAT |
| INN | cobicistat |
| Description | Cobicistat is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoic acid with the amino group of 1,3-thiazol-5-ylmethyl [(2R,5R)-5-amino-1,6-diphenylhexan-2-yl]carbamate. Acts as a pharmacoenhancer in treatment of HIV-1 by inhibiting P450 enzymes that metabolise other medications.. It has a role as a P450 inhibitor. It is a member of 1,3-thiazoles, a member of morpholines, a member of ureas, a carbamate ester and a monocarboxylic acid amide. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1 |
Identifiers
| PDB | — |
| CAS-ID | 1004316-88-4 |
| RxCUI | 1306284 |
| ChEMBL ID | CHEMBL2095208 |
| ChEBI ID | 72291 |
| PubChem CID | 25151504 |
| DrugBank | DB09065 |
| UNII ID | LW2E03M5PG (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Stribild - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Genvoya - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,495 documents
View more details
Safety
Black-box Warning
Black-box warning for: Genvoya, Stribild, Symtuza
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
17,594 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more